Introduction
Patients and methods
Study design and patient cohort
Variables | CYFRA 21 − 1 |
p
| Ki67 |
p
| ||
---|---|---|---|---|---|---|
Positive (n = 73) | Negative (n = 44) | High (n = 74) | Low (n = 43) | |||
Gender | 0.07 | 0.057 | ||||
Male (n, %) | 56 (76.71) | 27 (61.36) | 57 (77.02) | 26 (60.47) | ||
Female (n, %) | 17 (23.29) | 17 (38.64) | 17 (22.98) | 17 (39.53) | ||
Age (years) | < 0.001 | 0.563 | ||||
≥ 60 (n, %) | 59 (73.8) | 21 (47.73) | 52 (70.27) | 28 (65.12) | ||
< 60 (n, %) | 14 (37.8) | 23 (52.27) | 22 (29.73) | 15 (34.88) | ||
History of smoking | 0.021 | 0.544 | ||||
Never (n, %) | 41 (56.16) | 15 (34.09) | 37 (50.00) | 19 (44.19) | ||
Ever (n, %) | 32 (43.84) | 29 (65.91) | 37 (50.00) | 24 (55.81 | ||
Family history of tumors (n, %) | 0.268 | 0.695 | ||||
Yes (n, %) | 2 (2.74) | 0 (0) | 1 (1.35) | 1 (2.33) | ||
No (n, %) | 71 (97.26) | 44 (100.00) | 73 (98.65) | 42 (97.67) | ||
ECOG score | 0.012 | 0.838 | ||||
0–2 (n, %) | 57 (78.08) | 42 (95.45) | 63 (85.14) | 36 (83.72) | ||
3–4 (n, %) | 16 (21.92) | 2 (4.55) | 11 (14.86) | 7 (16.28) | ||
Histology | ||||||
Adenocarcinoma (n, %) | 35 (47.95) | 30 (68.18) | 39 (52.70) | 27 (62.79) | ||
Squamous cell carcinoma | 29 (39.73) | 6 (12.64) | 25 (33.78) | 12 (27.91) | ||
Others (n, %) | 9 (12.32) | 8 (18,18) | 10 (13.52) | 4 (9.30) | ||
TNM Stage | 0.976 | 0.332 | ||||
IIIB (n, %) | 28 (38.36) | 17 (38.64) | 26 (35.14) | 19 (44.19) | ||
IV (n, %) | 45 (61.64) | 27 (61.36) | 48 (64.86) | 24 (55.81) | ||
CEA | 0.55 | 0.431 | ||||
Positive (n, %) | 34 (46.58) | 23 (52.27) | 34 (45.95) | 23 (53.49) | ||
Negative (n, %) | 39 (53.42) | 21 (47.73) | 40 (54.05) | 20 (46.51) | ||
NSE | 0.007 | 0.588 | ||||
Positive (n, %) | 31 (42.47) | 8 (18.19) | 26 (36.49) | 24 (55.81) | ||
Negative (n, %) | 41 (57.53) | 36 (81.81) | 47 (63.51) | 19 (44.19) | ||
SCC | 0.903 | 0.205 | ||||
Positive (n, %) | 11 (15.07) | 7 (21.2) | 9 (12.16) | 9 (20.93) | ||
Negative (n, %) | 62 (84.93) | 37 (44.0) | 65 (87.84) | 34 (79.07) | ||
TTF-1 | 0.022 | 0.492 | ||||
Positive (n, %) | 56 (76.71) | 41 (93.18) | 60 (81.08) | 37 (86.05) | ||
Negative (n, %) | 17 (23.29) | 3 (6.82) | 14 (18.92) | 6 (13.95) | ||
CK-7 | 0.153 | 0.674 | ||||
Positive (n, %) | 53 (72.60) | 37 (84.09) | 56 (75.68) | 34 (79.07) | ||
Negative (n, %) | 20 (27.40) | 7 (15.91) | 18 (24.32) | 9 (20.93) | ||
Line of therapy | 0.965 | 0.497 | ||||
1st | 63 | 38 | 66 | 35 | ||
2nd | 6 | 4 | 5 | 5 | ||
>2nd | 4 | 2 | 3 | 3 |
Variables | Patients with EGFR mutations in advanced NSCLC |
---|---|
Gender, Female (n, %) | 20 (54.05) |
Age, ≥ 60 (n, %) | 26 (70.27) |
History of smoking, ever (n, %) | 29 (78.38) |
Family history of tumors, yes (n, %) | 0 (0) |
ECOG score, 0–2 (n, %) | 34 (91.89) |
Histology, Adenocarcinoma (n, %) | 37 (100) |
TNM Stage, IV (n, %) | 33 (89.19) |
CYFRA 21 − 1, Positive (n, %) | 24 (64.86) |
CEA, Positive (n, %) | 27 (72.97) |
NSE, Positive (n, %) | 13 (35.14) |
SCC, Positive (n, %) | 4 (10.81) |
Ki67, Positive (n, %) | 28 (75.68) |
TTF-1, Positive (n, %) | 32 (86.49) |
CK-7, Positive (n, %) | 31 (83.78) |
TKIs treatment | |
Gefitinib (n, %) | 29 (78.38) |
Others TKIs (n, %) | 8 (21.62) |
EGFR mutations | |
Exon 19 (n, %) | 18 (48.65) |
Exon 20 (n, %) | 3 (8.11) |
Exon 19 and 20 (n, %) | 4 (10.81) |
Exon 21 (n, %) | 10 (27.03) |
Exon 21 and 20 (n, %) | 1 (2.70) |
Exon 20 and 18 (n, %) | 1 (2.70) |
The measurement and analysis of serum tumor markers
Ki67 measurement and analysis
Mutation analysis
Statistical analysis
Results
Clinical and Laboratory characteristics for advanced NSCLC patients
The relevance of CYFRA 21 − 1 and Ki67 to survival in advanced NSCLC patients
The relevance of CYFRA 21 − 1 and Ki67 to survival in advanced NSCLC patients with wild-type EGFR
The relevance of CYFRA 21 − 1 and Ki67 to survival in advanced NSCLC patients with EGFR mutation
Univariate and multivariate cox analysis for OS in advanced NSCLC patients with wild-type EGFR
Variables | Univariate analysis | Multivariate cox analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI |
p
| HR | 95% CI |
p
| |
Gender | 1.007 | 0.622 ~ 1.629 | 0.979 | 0.867 | 0.450 ~ 1.669 | 0.670 |
Age (years) | 1.035 | 1.012 ~ 1.058 | 0.002 | 1.031 | 1.003 ~ 1.006 | 0.028 |
Histopathology | 1.357 | 0.933 ~ 1.975 | 0.111 | 1.760 | 1.152 ~ 2.690 | 0.009 |
TNM stage | 1.534 | 0.935 ~ 2.470 | 0.078 | |||
ECOG score (> 2) | 2.316 | 1.361 ~ 3.939 | 0.002 | |||
Smoking history (ever) | 0.988 | 0.632 ~ 1.546 | 0.958 | |||
CEA (positive) | 1.170 | 0.708 ~ 1.733 | 0.655 | |||
SCC | 0.859 | 0.306 ~ 2.415 | 0.774 | |||
CYFRA21-1 (positive) | 2.538 | 1.509 ~ 4.268 | 0.001 | 2.304 | 1.224 ~ 4.335 | 0.01 |
TTF-1 (positive) | 0.711 | 0.404 ~ 1.251 | 0.237 | |||
CK-7 (positive) | 0.863 | 0.509 ~ 1.463 | 0.584 | |||
Ki67 (High) | 2.055 | 0.943 ~ 4.481 | 0.070 | 2.130 | 1.242 ~ 3.652 | 0.006 |